ProJenX launches to advance novel, targeted therapies for ALS and other brain diseases

/PRNewswire/ -- ProJenX, a New York City-based, clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined...

Related Keywords

New York ,United States ,Columbia University ,Columbia Center ,Erin Fleming ,Valerie Estess ,Hynek Wichterle ,Jenifer Estess ,Eric Heil ,Prnewswire Projen ,Excellence Capital ,Brentr Stockwell At Columbia University ,Chemistry At Columbia University ,Projenx Co ,New York City Based ,Medical Excellence Capital ,Motor Neuron Biology ,Lou Gehrig ,Cell Biology ,Biological Sciences ,Projenx Co Founder ,Board Director ,Senior Director ,Projenx Interim ,Medical Excellence Capital Managing Partner ,Projenx ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,New Products Amp Services ,Venture Capital ,